Literature DB >> 12102380

Characterizing the effects of sertraline in post-traumatic stress disorder.

J R T Davidson1, L R Landerman, G M Farfel, C M Clary.   

Abstract

BACKGROUND: Sertraline has a proved efficacy in post-traumatic stress disorder (PTSD), but it is unknown which symptoms respond or in what sequence this occurs. Such information might be useful clinically and heuristically.
METHOD: The study examined the effects of sertraline on the individual symptoms of PTSD. It also examined whether early changes in anger explained drug-induced change in other symptoms over time. Mixed models analysis was applied to datasets from two 12-week placebo-controlled trials of sertraline. A validated self-rating scale (DTS) was used to assess treatment efficacy.
RESULTS: Sertraline was superior to placebo on 15 of 17 symptoms, especially in the numbing and hyperarousal clusters. A strong effect was found on anger from week 1, which partly explained the subsequent effects of sertraline on other symptoms, some of which began to show significantly greater response to drug than to placebo at week 6 (emotional upset at reminders, anhedonia, detachment, numbness, hypervigilance) and week 10 (avoidance of activities, foreshortened future).
CONCLUSIONS: Sertraline exercises a broad spectrum effect in PTSD. Effects are more apparent on the psychological rather than somatic symptoms of PTSD, with an early modulation of anger and, perhaps, other affects, preceding improvement in other symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102380     DOI: 10.1017/s0033291702005469

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  9 in total

1.  Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.

Authors:  Kathryn M Connor; Jonathan R T Davidson; Richard H Weisler; Wei Zhang; Kurian Abraham
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

2.  Do changes in trauma-related beliefs predict PTSD symptom improvement in prolonged exposure and sertraline?

Authors:  Andrew A Cooper; Lori A Zoellner; Peter Roy-Byrne; Matig R Mavissakalian; Norah C Feeny
Journal:  J Consult Clin Psychol       Date:  2017-05-15

Review 3.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Pharmacotherapy for post traumatic stress disorder (PTSD).

Authors:  Taryn Williams; Nicole J Phillips; Dan J Stein; Jonathan C Ipser
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

5.  Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder.

Authors:  Fabio Pibiri; Marianela Nelson; Alessandro Guidotti; Erminio Costa; Graziano Pinna
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

6.  Changes in emotion regulation in adults with and without a history of childhood abuse following posttraumatic stress disorder treatment.

Authors:  Alissa B Jerud; Lori A Zoellner; Larry D Pruitt; Norah C Feeny
Journal:  J Consult Clin Psychol       Date:  2014-04-07

7.  Characterizing the Effects of Quetiapine in Military Post-Traumatic Stress Disorder.

Authors:  Gerardo Villarreal; Mark B Hamner; Clifford Qualls; José M Cañive
Journal:  Psychopharmacol Bull       Date:  2018-02-05

Review 8.  Pharmacotherapy for post traumatic stress disorder (PTSD).

Authors:  D J Stein; J C Ipser; S Seedat
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

9.  The Relative Effects of Prazosin on Individual PTSD Symptoms: Evidence for Pathophysiologically-Related Clustering.

Authors:  Rebecca C Hendrickson; Steven P Millard; Kathleen F Pagulayan; Elaine R Peskind; Murray A Raskind
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.